Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023
Introduction Nuvaxovid became available in Australia from February 2022, a year after the first COVID-19 vaccines. This protein-based vaccine was an alternative for people who had had an adverse event to and/or were hesitant to receive an mRNA or adenovirus-based COVID-19 vaccine. Although safety fr...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Centre for Disease Prevention and Control
2024-12-01
|
| Series: | Eurosurveillance |
| Subjects: | |
| Online Access: | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.50.2400164 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|